Skip to main content
SpringerLink
Log in
Book cover

Contrast Media pp 199–204Cite as

Gadolinium-Based Contrast Agents

  • Chapter

  • 1079 Accesses

Part of the book series: Medical Radiology ((Med Radiol Diagn Imaging))

Although nonspecific extracellular gadolinium (Gd) chelates dominate the MR contrast agent market, organ-specific contrast agents (Gd-based and non- Gd-based) have tissue-specific properties that permit targeted MRI of organs such as the liver and lymph nodes or MR angiography. Gadoliniumbased organ-specific contrast agents (Table 25.1) are increasingly used to detect and characterize liver lesions better ( Bellin et al. 1994, 2003; Bluemke et al. 2005; Kirchin and Runge 2003; Kopp et al. 1997; Marti-Bonmati et al. 2003; Ros et al. 1995; Spinazzi et al. 1999) and to improve the efficacy of MR angiography ( Rapp et al. 2005; Goyen et al. 2005; Nikolaou et al. 2006). Although there are theoretical safety concerns, these MR contrast agents have been shown to be safe and welltolerated in clinical use.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   109.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Bellin MF, Zaim S, Auberton E et al (1994) Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging. Radiology 193:657–663

    PubMed  CAS  Google Scholar 

  • Bellin MF, Vasile M, Morel-Precetti S (2003) Currently used non-specific extracellular MR contrast media. Eur Radiol 13:2688–2698

    Article  PubMed  CAS  Google Scholar 

  • Bluemke AD, Sahani D, Amendola M et al (2005) Efficacy and safety of MR imaging with liver specific contrast agent: US multicenter phase III study. Radiology 237:89–98

    Article  PubMed  Google Scholar 

  • Bollow M, Taupitz M, Hamm B et al (1997) Gadolinium-ethoxybenzyl-DTPA as a hepatobiliary contrast agent for use in MR cholangiography: results of an in vivo phase-I clinical evaluation. Eur Radiol 7:126–132

    Article  PubMed  CAS  Google Scholar 

  • Bosch E, Kreitner KF, Peirano MF et al (2008) Safety and efficacy of gadofosveset-enhanced MR angiography for evaluation of pedal arterial disease: multicenter comparative phase 3 study. Am J Roentgenol 190:179–186

    Article  Google Scholar 

  • Breuer J, Balzer T, Shamsi K et al (2003) Clinical experience from phase II and phase III studies for Gd-EOB-DTPA: a new liver specific MR contrast agent. Eur Radiol 13 (Suppl 2):S109

    Google Scholar 

  • Caravan P, Comuzzi C, Crooks W et al (2001) Thermodynamic stability and kinetic inertness of MS-325, a new blood pool agent for magnetic resonance imaging. Inorg Chem 40:2170–2176

    Article  PubMed  CAS  Google Scholar 

  • Caudana R, Morana G, Pirovano GP et al (1996) Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA) — preliminary results of phase II clinical application. Radiology 199:513–520

    PubMed  CAS  Google Scholar 

  • Cavagna FM, Maggioni F, Castelli PM et al (1997) Gadolinium chelates with weak binding to serum proteins: a new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 32:780–796

    Article  PubMed  CAS  Google Scholar 

  • Dohr O, Hofmeister R, Treher M, Schweinfurth H (2007) Preclinical safety evaluation of Gd-EOB-DTPA (Primovist). Invest Radiol 42:830–841

    Article  PubMed  CAS  Google Scholar 

  • Giovagnoni A, Paci E (1996) Liver III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/ Dimeg). Magn Reson Imaging Clin North Am 4:61–72

    CAS  Google Scholar 

  • Goyen M, Edelman M, Perreault P et al (2005) MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325. Radiology 236:825–833

    Article  PubMed  Google Scholar 

  • Grazioli L, Morana G, Caudana R et al (2000) Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathological findings. Invest Radiol 35:25–34

    Article  PubMed  CAS  Google Scholar 

  • Halavaara J, Breuer J, Ayuso C et al (2006) Liver tumor characterization: comparison between liver-specific Gd-EOB-DTPA -enhanced MRI and biphasic CT: a multicenter trial. J Comput Assist Tomogr 30:345–354

    Article  PubMed  Google Scholar 

  • Hamm B, Staks T, Mühler A et al (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–792

    PubMed  CAS  Google Scholar 

  • Hamm B, Kirchin M, Pirovano G et al (1999) Clinical utility and safety of MultiHance in magnetic resonance imaging of liver cancer: results of multicenter studies in Europe and the USA. J Comput Assist Tomogr 23(Suppl 1): S53–S60

    PubMed  Google Scholar 

  • Huppertz A, Balzer T, Blakeborough A et al for the European EOB Study Group (2004) Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 230:266–275

    Article  PubMed  Google Scholar 

  • Kato N, Yokawa T, Tamura A et al (2002) Gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic acid interaction with clinical drugs in rats. Invest Radiol 37:680–684

    Article  PubMed  CAS  Google Scholar 

  • Kirchin MA, Runge VM (2003) Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging 14:426–435

    Article  PubMed  Google Scholar 

  • Kirchin MA, Pirovano G, Spinazzi A (1998) Gadobenate dimeglumine (Gd-BOPTA): an overview. Invest Radiol 33:798–809

    Article  PubMed  CAS  Google Scholar 

  • Kirchin MA, Pirovano G, Venetianer C et al (2001) Safety assessment of gadobenate dimeglumine (MultiHance): extended clinical experience from phase I studies to post-marketing surveillance. J Magn Reson Imaging 14:281–294

    Article  PubMed  CAS  Google Scholar 

  • Kuwatsuru R, Kadoya M, Ohtomo K et al (2001) Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors. Invest Radiol 36:632–641

    Article  PubMed  CAS  Google Scholar 

  • Lin SP and Brown JJ (2007) MR contrast agents: physical and pharmacologic basics. J Magn Reson Imaging 25:884–899

    Article  PubMed  Google Scholar 

  • Manfredi R, Maresca G, Baron RL et al (1998) Gadobenate dimeglumine (BOPTA)-enhanced MR imaging: patterns of enhancement in normal liver and cirrhosis. J Magn Reson Imaging 8:862–867

    Article  PubMed  CAS  Google Scholar 

  • Manfredi R, Maresca G, Baron RL et al (1999) Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA). J Magn Reson Imaging 9:704–710

    Article  PubMed  CAS  Google Scholar 

  • Nikolaou K, Kramer H, Grosse D et al (2006) High-spatial-resolution multistation MR angiography with parallel imaging and blood pool agent: initial experience. Radiology 241:861–872

    Article  PubMed  Google Scholar 

  • Perreault P, Edelman MA, Baum RA et al (2003) MR angiography with gadofosveset trisodium for peripheral vascular disease phase II trial. Radiology 229:811–820

    Article  PubMed  Google Scholar 

  • Peterstein J, Spinazzi A, Giovagnoni A et al (2000) Evaluation of the efficacy of gadobenate dimeglumine in magnetic resonance imaging of focal liver lesions: a multicenter phase III clinical study. Radiology 215:727–736

    Google Scholar 

  • Rapp JH, Wolff SD, Quinn JA et al (2005) Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography— Multicenter comparative phase III study. Radiology 236:71–78

    Article  PubMed  Google Scholar 

  • Reimer P, Rummeny EJ, Shamsi K et al (1996) Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 199:177–183

    PubMed  CAS  Google Scholar 

  • Reimer P, Schneider G, Schima W (2004) Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 14:559–578

    Article  PubMed  Google Scholar 

  • Rosati G, Pirovano G, Spinazzi A (1994) Interim results of phase II clinical testing of gadobenate dimeglumine. Invest Radiol 29:S183–S185

    Article  PubMed  Google Scholar 

  • Schuhmann-Giampieri G, Schmitt-Willich H, Press WR et al (1992) Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 183:59–64

    PubMed  CAS  Google Scholar 

  • Shamsi K, Yucel EK, Chamberlin P (2006) A summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: phase II and phase III clinical trials data. Invest Radiol 41:822–830

    Article  PubMed  CAS  Google Scholar 

  • Shellock FG, Parker JR, Pirovano G et al (2006) Safety characteristics of gadobenate dimeglumine: clinical experience from intra- and interindividual comparison studies with gadopentetate dimeglumine. J Magn Reson Imaging 24: 1378–1385

    Article  PubMed  Google Scholar 

  • Spinazzi A, Lorusso V, Pirovano G et al (1999) Safety, tolerance, biodistribution and MR imaging enhancement of the liver with Gd-BOPTA: results of clinical pharmacologic and pilot imaging studies in non-patient and patient volunteers. Acad Radiol 6:282–291

    Article  PubMed  CAS  Google Scholar 

  • Steger-Hartmann T, Graham PB, Müller S, Schweinfurth H (2006) Preclinical safety assessment of Vasovist (gadofosveset trisodium), a new paramagnetic resonance imaging contrast agent for angiography. Invest Radiol 41:449–459

    Article  PubMed  Google Scholar 

  • Stenver DI (2008) Pharmacovigilance: What to do if you see an adverse reaction and the consequences. Eur J Radiol 66:184–186

    Article  PubMed  Google Scholar 

  • Stern W, Schick F, Kopp AF et al (2000) Dynamic MR imaging of liver metastases with Gd-EOB-DTPA. Acta Radiol 41: 255–262

    Article  PubMed  CAS  Google Scholar 

  • Vogl TJ, Stupavsky A, Pegios W et al (1997) Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation. Radiology 205:721–728

    PubMed  CAS  Google Scholar 

  • Weinmann HJ, Schuhmann-Gampieri G, Schmitt-Willich H et al (1992) A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 22: 233–237

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. AP-HP, Service de Radiologie, Hôpital Paul Brousse, Université Paris-Sud 11, 12-14 avenue Paul Vaillant Couturier, 94804, Villejuif Cedex, France

    Marie France Bellin

Authors
  1. Marie France Bellin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Diagnostic Radiology, Copenhagen University Hospital, Herlev

    Henrik S. Thomsen MD (Professor of Radiology Consultant, Director) (Professor of Radiology Consultant, Director)

  2. Department of Diagnostic Sciences Faculty of Health Sciences, University of Copenhagen, Herlev Ringvej 75, 2730, Herlev, Denmark

    Henrik S. Thomsen MD (Professor of Radiology Consultant, Director) (Professor of Radiology Consultant, Director)

  3. Department of Radiology St. Bartholomew’s Hospital, University of London, West Smithfield, London, EC1A 7BE, UK

    Judith A. W. Webb MD, FRCP, FRCR (Consultant (retired) (Consultant (retired)

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Bellin, M.F. (2009). Gadolinium-Based Contrast Agents. In: Thomsen, H.S., Webb, J.A.W. (eds) Contrast Media. Medical Radiology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72784-2_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-72784-2_25

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-72783-5

  • Online ISBN: 978-3-540-72784-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation